Medical Infralytix Pvt Ltd Press Releases

Moderna claimed promising findings from a small-sample study of their experimental customized cancer vaccine and Merck's Keytruda to treat patients with head and neck cancer.

Moderna (MRNA) shares rose on Wednesday after the firm said that its experimental flu shot beat widely used vaccinations from Sanofi and GSK.

Madrigal Pharmaceuticals (MDGL) said Wednesday that it expects to get FDA clearance for its nonalcoholic steatohepatitis medication in March, sending the company's shares skyrocketing.

After Eli Lilly (LLY) decided to buy the biopharma company for $2.4 billion, shares of DICE Therapeutics (DICE) rocketed and reached an all-time high on Tuesday morning.

Investors gambled on Novavax Inc. (NVAX) as a coronavirus vaccine winner in the early days of the pandemic. In just one year, the stock increased by a mind-boggling 2,700%.

Novavax Inc. (NVAX) shares have lost more than 68% of their value this year. The heyday of NVAX as a high-flying pandemic stock looks to be over

Novavax Inc. (NVAX) rocketed higher on Tuesday, despite the market's overall poor performance. At roughly 12:35 p.m., the stock was up 5.8% from the previous day's closing. With an increase of roughly 1.9% to $56.55 at the close.

The bad news is that NVAX isn't outperforming the market today. The biotech company's stock has dropped 56% this year, while the S&P 500 has dropped roughly 6%. NVAX's stock has risen more than 3,400% in the last two years.

On February 7th, ZBH announced that its Board of Directors has declared a pro rata dividend of 80.3% of ZimVie Inc.'s outstanding common shares to Zimmer Biomet stockholders of record on February 15, 2022.

ABBV, a pharmaceutical business, had its stock tumble 10.5%. The 52-week low for the stock is $105.56 and the 52-week high is $175.91.